mRNA-Based Vaccines
Salvato in:
| Pubblicato in: | Vaccines vol. 9, no. 4 (2021), p. 390 |
|---|---|
| Autore principale: | |
| Altri autori: | , , , , |
| Pubblicazione: |
MDPI AG
|
| Soggetti: | |
| Accesso online: | Citation/Abstract Full Text + Graphics Full Text - PDF |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 2528258239 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 2076-393X | ||
| 024 | 7 | |a 10.3390/vaccines9040390 |2 doi | |
| 035 | |a 2528258239 | ||
| 045 | 2 | |b d20210101 |b d20211231 | |
| 084 | |a 231639 |2 nlm | ||
| 100 | 1 | |a Kowalzik, Frank |u Pediatric Department, University Medical Center of the Johannes Gutenberg-University, 55128 Mainz, Germany; <email>daniel.schreiner@unimedizin-mainz.de</email> (D.S.); <email>christian.jensen@unimedizin-mainz.de</email> (C.J.); <email>Stephan.Gehring@unimedizin-mainz.de</email> (S.G.); <email>fred.zepp@unimedizin-mainz.de</email> (F.Z.) | |
| 245 | 1 | |a mRNA-Based Vaccines | |
| 260 | |b MDPI AG |c 2021 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Increases in the world’s population and population density promote the spread of emerging pathogens. Vaccines are the most cost-effective means of preventing this spread. Traditional methods used to identify and produce new vaccines are not adequate, in most instances, to ensure global protection. New technologies are urgently needed to expedite large scale vaccine development. mRNA-based vaccines promise to meet this need. mRNA-based vaccines exhibit a number of potential advantages relative to conventional vaccines, namely they (1) involve neither infectious elements nor a risk of stable integration into the host cell genome; (2) generate humoral and cell-mediated immunity; (3) are well-tolerated by healthy individuals; and (4) are less expensive and produced more rapidly by processes that are readily standardized and scaled-up, improving responsiveness to large emerging outbreaks. Multiple mRNA vaccine platforms have demonstrated efficacy in preventing infectious diseases and treating several types of cancers in humans as well as animal models. This review describes the factors that contribute to maximizing the production of effective mRNA vaccine transcripts and delivery systems, and the clinical applications are discussed in detail. | |
| 653 | |a RNA polymerase | ||
| 653 | |a Pathogens | ||
| 653 | |a mRNA vaccines | ||
| 653 | |a Vaccines | ||
| 653 | |a Population density | ||
| 653 | |a Severe acute respiratory syndrome coronavirus 2 | ||
| 653 | |a Genomes | ||
| 653 | |a Infectious diseases | ||
| 653 | |a Adaptation | ||
| 653 | |a Market entry | ||
| 653 | |a Animal models | ||
| 653 | |a Proteins | ||
| 653 | |a Protein synthesis | ||
| 653 | |a Gene expression | ||
| 653 | |a Viruses | ||
| 653 | |a System effectiveness | ||
| 653 | |a Antigens | ||
| 653 | |a Streptococcus infections | ||
| 653 | |a Vectors (Biology) | ||
| 653 | |a New technology | ||
| 653 | |a Vaccine development | ||
| 653 | |a Manufacturing | ||
| 653 | |a Humoral immunity | ||
| 653 | |a Cell-mediated immunity | ||
| 653 | |a Laboratories | ||
| 653 | |a Economic | ||
| 700 | 1 | |a Schreiner, Daniel |u Pediatric Department, University Medical Center of the Johannes Gutenberg-University, 55128 Mainz, Germany; <email>daniel.schreiner@unimedizin-mainz.de</email> (D.S.); <email>christian.jensen@unimedizin-mainz.de</email> (C.J.); <email>Stephan.Gehring@unimedizin-mainz.de</email> (S.G.); <email>fred.zepp@unimedizin-mainz.de</email> (F.Z.) | |
| 700 | 1 | |a Jensen, Christian |u Pediatric Department, University Medical Center of the Johannes Gutenberg-University, 55128 Mainz, Germany; <email>daniel.schreiner@unimedizin-mainz.de</email> (D.S.); <email>christian.jensen@unimedizin-mainz.de</email> (C.J.); <email>Stephan.Gehring@unimedizin-mainz.de</email> (S.G.); <email>fred.zepp@unimedizin-mainz.de</email> (F.Z.) | |
| 700 | 1 | |a Teschner, Daniel |u Department of Hematology, Medical Oncology, and Pneumology, University Medical Center of the Johannes Gutenberg University, 55122 Mainz, Germany; <email>daniel.teschner@unimedizin-mainz.de</email> | |
| 700 | 1 | |a Gehring, Stephan |u Pediatric Department, University Medical Center of the Johannes Gutenberg-University, 55128 Mainz, Germany; <email>daniel.schreiner@unimedizin-mainz.de</email> (D.S.); <email>christian.jensen@unimedizin-mainz.de</email> (C.J.); <email>Stephan.Gehring@unimedizin-mainz.de</email> (S.G.); <email>fred.zepp@unimedizin-mainz.de</email> (F.Z.) | |
| 700 | 1 | |a Zepp, Fred |u Pediatric Department, University Medical Center of the Johannes Gutenberg-University, 55128 Mainz, Germany; <email>daniel.schreiner@unimedizin-mainz.de</email> (D.S.); <email>christian.jensen@unimedizin-mainz.de</email> (C.J.); <email>Stephan.Gehring@unimedizin-mainz.de</email> (S.G.); <email>fred.zepp@unimedizin-mainz.de</email> (F.Z.) | |
| 773 | 0 | |t Vaccines |g vol. 9, no. 4 (2021), p. 390 | |
| 786 | 0 | |d ProQuest |t Biological Science Database | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/2528258239/abstract/embedded/75I98GEZK8WCJMPQ?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text + Graphics |u https://www.proquest.com/docview/2528258239/fulltextwithgraphics/embedded/75I98GEZK8WCJMPQ?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/2528258239/fulltextPDF/embedded/75I98GEZK8WCJMPQ?source=fedsrch |